Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal

Detalhes bibliográficos
Autor(a) principal: Gouveia, Miguel
Data de Publicação: 2015
Outros Autores: Sousa, Rita, Costa, João, Borges, Margarida
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.14/34034
Resumo: Background: According to a recent Portuguese study the prevalence of lifetime consumption of heroin in the global population (age range: 15-74 years) is 0.5%. Methadone is the standard pharmacological treatment, while buprenorphine has been available since 1999 as an alternative treatment. Nevertheless, no comparative economic evaluation of the costeffectiveness of these therapies has been made available. Aim: This study estimates the cost-effectiveness and cost-utility of a fixed dose combination of buprenorphine-naloxone (B/N) versus methadone as substitution treatments for opioid drug dependence from the Portuguese social perspective. Material and Methods: The comparator for B/N was methadone treatment, which is the most common pharmacological therapy and current clinical practice in Portugal. Health gains were measured using the number of heroin-free days per year (indicator of effectiveness) and quality-adjusted life years (QALYs) associated with each treatment. Estimated costs included acquisition, preparation and transport of medication; costs of dispensing and supervision of administration; costs arising from the periodic monitoring of patients and the nonmedical direct costs of crime associated with drug addiction. Results: The B/N combination is associated with an incremental cost-utility ratio of €5,914 per QALY gained. The B/N combination is dominant when the analysis includes costs of crime associated with drug addiction. Conclusions: The results suggest that this combination is cost-effective and has the potential to generate health gains in the target population at a low cost.
id RCAP_dbb8999f556d0d83d7db98049cc8fbd0
oai_identifier_str oai:repositorio.ucp.pt:10400.14/34034
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in PortugalCost-effectivenessCost-utilityMethadoneOpioid dependenceSuboxoneBackground: According to a recent Portuguese study the prevalence of lifetime consumption of heroin in the global population (age range: 15-74 years) is 0.5%. Methadone is the standard pharmacological treatment, while buprenorphine has been available since 1999 as an alternative treatment. Nevertheless, no comparative economic evaluation of the costeffectiveness of these therapies has been made available. Aim: This study estimates the cost-effectiveness and cost-utility of a fixed dose combination of buprenorphine-naloxone (B/N) versus methadone as substitution treatments for opioid drug dependence from the Portuguese social perspective. Material and Methods: The comparator for B/N was methadone treatment, which is the most common pharmacological therapy and current clinical practice in Portugal. Health gains were measured using the number of heroin-free days per year (indicator of effectiveness) and quality-adjusted life years (QALYs) associated with each treatment. Estimated costs included acquisition, preparation and transport of medication; costs of dispensing and supervision of administration; costs arising from the periodic monitoring of patients and the nonmedical direct costs of crime associated with drug addiction. Results: The B/N combination is associated with an incremental cost-utility ratio of €5,914 per QALY gained. The B/N combination is dominant when the analysis includes costs of crime associated with drug addiction. Conclusions: The results suggest that this combination is cost-effective and has the potential to generate health gains in the target population at a low cost.Veritati - Repositório Institucional da Universidade Católica PortuguesaGouveia, MiguelSousa, RitaCosta, JoãoBorges, Margarida2021-06-28T15:06:23Z20152015-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.14/34034eng1592-163884931394483000357247100005info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-15T01:42:23Zoai:repositorio.ucp.pt:10400.14/34034Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:27:32.777875Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal
title Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal
spellingShingle Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal
Gouveia, Miguel
Cost-effectiveness
Cost-utility
Methadone
Opioid dependence
Suboxone
title_short Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal
title_full Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal
title_fullStr Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal
title_full_unstemmed Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal
title_sort Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal
author Gouveia, Miguel
author_facet Gouveia, Miguel
Sousa, Rita
Costa, João
Borges, Margarida
author_role author
author2 Sousa, Rita
Costa, João
Borges, Margarida
author2_role author
author
author
dc.contributor.none.fl_str_mv Veritati - Repositório Institucional da Universidade Católica Portuguesa
dc.contributor.author.fl_str_mv Gouveia, Miguel
Sousa, Rita
Costa, João
Borges, Margarida
dc.subject.por.fl_str_mv Cost-effectiveness
Cost-utility
Methadone
Opioid dependence
Suboxone
topic Cost-effectiveness
Cost-utility
Methadone
Opioid dependence
Suboxone
description Background: According to a recent Portuguese study the prevalence of lifetime consumption of heroin in the global population (age range: 15-74 years) is 0.5%. Methadone is the standard pharmacological treatment, while buprenorphine has been available since 1999 as an alternative treatment. Nevertheless, no comparative economic evaluation of the costeffectiveness of these therapies has been made available. Aim: This study estimates the cost-effectiveness and cost-utility of a fixed dose combination of buprenorphine-naloxone (B/N) versus methadone as substitution treatments for opioid drug dependence from the Portuguese social perspective. Material and Methods: The comparator for B/N was methadone treatment, which is the most common pharmacological therapy and current clinical practice in Portugal. Health gains were measured using the number of heroin-free days per year (indicator of effectiveness) and quality-adjusted life years (QALYs) associated with each treatment. Estimated costs included acquisition, preparation and transport of medication; costs of dispensing and supervision of administration; costs arising from the periodic monitoring of patients and the nonmedical direct costs of crime associated with drug addiction. Results: The B/N combination is associated with an incremental cost-utility ratio of €5,914 per QALY gained. The B/N combination is dominant when the analysis includes costs of crime associated with drug addiction. Conclusions: The results suggest that this combination is cost-effective and has the potential to generate health gains in the target population at a low cost.
publishDate 2015
dc.date.none.fl_str_mv 2015
2015-01-01T00:00:00Z
2021-06-28T15:06:23Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.14/34034
url http://hdl.handle.net/10400.14/34034
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1592-1638
84931394483
000357247100005
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131993589415936